John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.
Chief Insights in Oncology
John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.
EP. 3: Sustaining Cancer Research and Oncology: A Call to Congress
Published: | Updated:
Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of Chief Insights in Oncology.
EP. 4: Dr Burke on the Exciting Potential of Trispecific Antibodies
Published: | Updated:
A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.
Discover how recent studies shift minimal residual disease testing from a prognostic tool to a key player in managing hematological malignancies.